YehudaZPattMD
Oncology • Albuquerque, NMGastrointestinal Cancer, Hematologic Oncology
Professor of Medicine, University of New Mexico. Director of Gastrointestinal Oncology Research at the University of New Mexico. Professor, Department of Internal Medicine, Division of Hematology/Oncology
Dr. Patt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1201 Camino de Salud NE
Albuquerque, NM 87102Phone+1 505-272-3120Fax+1 505-272-8060
Summary
- Yehuda Patt is a liver cancer specialist, gastrointestinal oncologist, and Professor of Medicine at the University of New Mexico, and resides in Santa Fe, New Mexico. He was previously at the University of Texas, MD Anderson Cancer Center between the years 1975- 2003. He is the author of various papers pertaining to cancer and their effects on people, and has been cited numerous times for his writings and analyses.
Patt is currently the director of Gastrointestinal Oncology Research at the University of New Mexico, as well as a professor in the Department of Internal Medicine, Division of Hematology/Oncology.
Education & Training
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1967
Certifications & Licensure
NM State Medical License 1994 - 2025
TX State Medical License 1976 - 2021
MD State Medical License 2002 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter Start of enrollment: 2005 Oct 01
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
- Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Start of enrollment: 2007 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.Manal M Hassan, Donghui Li, Younghun Han, Jinyoung Byun, Rikita I Hatia
Hepatology. 2024-07-01 - 13 citationsPhase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal CancerEmilio P. Araujo‐Mino, Yehuda Z. Patt, Cristina Murray‐Krezan, Joshua A. Hanson, Pranshu Bansal
The Oncologist. 2018-01-01 - 70 citationsEstrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular CarcinomaManal Hassan, Gehan Botrus, Reham Abdel-Wahab, Robert A. Wolff, Donghui Li
Clinical Gastroenterology and Hepatology. 2017-11-01
Professional Memberships
- Member
Other Languages
- French, German, Polish, Arabic, Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
